Glucose-Lowering Therapies in Patients With Concomitant Diabetes Mellitus and Heart Failure: Finding the “Sweet Spot” ∗

JACC: Heart Failure

Volumn 6, Issue 1, 2018, Pages 27-29

  Butler, Javed ^a   Vaduganathan, Muthiah ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

clinical trials; diabetes; heart failure; therapeutics

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; HEMOGLOBIN A1C; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; GLUCOSE;

ALL CAUSE HOSPITALIZATION; ALL CAUSE MORTALITY; CARDIOVASCULAR RISK; ECHOCARDIOGRAPHY; EDITORIAL; GLYCEMIC CONTROL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; UNITED KINGDOM;

DIABETES MELLITUS, TYPE 2; GLUCOSE; HEART FAILURE; HOSPITALIZATION; HUMANS; UNITED KINGDOM;

EID: 85030852103     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.09.002     Document Type: Editorial

References (6)

1. Fitchett, D., Butler, J., van de Borne, P., et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. Eur Heart J, 2017 Aug 28 [E-pub ahead of print].
2. Lawson, C.A., Jones, P.W., Teece, L., et al. Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population: stratification by diabetic glycemic control and medication intensification. J Am Coll Cardiol HF 6 (2018), 18–26.
3. McMurray, J.J.V., Ponikowski, P., Bolli, G.B., et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. J Am Coll Cardiol HF 6 (2018), 8–17.
4. Vaduganathan, M., Patel, R.B., Butler, J., Metra, M., Integrating electronic health records into the study of heart failure: promises and pitfalls. Eur J Heart Fail 19 (2017), 1128–1130.
5. Bangalore, S., Fayyad, R., Laskey, R., DeMicco, D.A., Messerli, F.H., Waters, D.D., Body-weight fluctuations and outcomes in coronary disease. N Engl J Med 376 (2017), 1332–1340.
6. Butler, J., Hamo, C.E., Filippatos, G., et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail 19 (2017), 1390–1400.